Alligator Bioscience to Participate in Upcoming Scientific and Investor Conferences in Q4 2024

October 30, 2024 3:50 AM

LUND, SE / ACCESSWIRE / October 30, 2024 / Alligator Bioscience (STO:ATORX) Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces participation in the following conferences during Q4 2024:Investors and Partnering ConferencesØU Life Science Investor Conference , October 30, CopenhagenSøren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments and upcoming catalysts...

Read more

Hemogenyx Pharmaceuticals PLC Announces Schedule for Phase I Clinical Trial Opening

October 30, 2024 3:00 AM

LONDON, UK / ACCESSWIRE / October 30, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a biopharmaceutical company focused on developing breakthrough therapies for blood diseases, is pleased to announce the schedule for the opening of the first clinical site for its lead asset, HEMO-CAR-T, formally designated HG-CT-1, targeting relapsed/refractory (R/R) acute myeloid leukemia (AML) in adults.The Company has successfully completed the necessary...

Read more

Alligator Bioscience and Aptevo Therapeutics to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024

October 29, 2024 11:15 AM

LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / October 29, 2024 / Alligator Bioscience AB ("Alligator") (STO:ATORX)(ATORX) and Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO) today announced that new, positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 will be presented in a poster session on Friday, November 8, 2024, at the Society for Immunotherapy of Cancer 2024 (SITC), taking place November 6th -...

Read more

Invitation to Presentation of BioInvent’s Interim Report January - September 2024

October 29, 2024 5:35 AM

LUND, SE / ACCESSWIRE / October 29, 2024 / BioInvent International (STO:BINV)BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) invites investors, analysts and the press to a presentation of the interim report January- September 2024 at 5:00 pm CET on Thursday October 31. The report will be published at 8:00 am CET the same day.BioInvent's CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The...

Read more

Tanvex CDMO to Exhibit at the 15th Annual World ADC Conference in San Diego

October 28, 2024 2:15 PM

SAN DIEGO, CA / ACCESSWIRE / October 28, 2024 / Tanvex CDMO announced its participation as an exhibitor in the 15th Annual World ADC Conference, taking place from November 4-7, 2024, at the Town & Country San Diego. Attendees are invited to visit Booth #416 to connect with the Tanvex CDMO team of experts, explore collaboration opportunities, and share insights on the latest trends in bispecific process development and formulation, cell-based...

Read more

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

October 28, 2024 9:00 AM

TH104, the Company's lead candidate for moderate-to-severe pruritus in chronic liver disease, showed no opioid withdrawal effects, reinforcing safety profileTH104 was well tolerated with no unexpected treatment-emergent adverse events, supporting further clinical developmentCompany expects Phase 2 topline data for chronic pruritus in primary biliary cholangitis (PBC) patients in 2025BRIDGEWATER, NJ / ACCESSWIRE / October 28, 2024 / Tharimmune,...

Read more

enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)

October 28, 2024 8:30 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the successful start to its six-month pre-clinical GLP study for enVVe, its transcatheter-delivered replacement venous valve. The first wave of implants, for the long-term subjects, was successfully completed, with the final wave for the shorter-term subjects scheduled for December....

Read more

Nature Cell's JointStem Has Been Designated as a Regenerative Medicine Advanced Therapy (RMAT) by the U.S. FDA

October 25, 2024 11:00 AM

LOS ANGELES, CA / ACCESSWIRE / October 25, 2024 / On October 23rd, Nature Cell Co., Ltd. proudly announced the receipt of RMAT designation for "JointStem," an innovative treatment for severe degenerative arthritis, from the U.S. FDA.The RMAT initiative by the U.S. FDA is designed to accelerate the development and approval of groundbreaking regenerative drugs that tackle critical medical needs, a revision made under the 21st Century Cures Act in...

Read more

Tharimmune Announces Upcoming Conference Presentations

October 25, 2024 8:00 AM

BRIDGEWATER, NJ / ACCESSWIRE / October 25, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be participating in two upcoming conferences.Nir Barak, M.D., Chief Medical Advisor, will present new results from the Company's Phase 1 trial of TH104 in a poster titled "P1780:...

Read more

English Edition of 'Stem Cells: The Secret of Reverse- Aging' by Dr. Jeong Chan Ra Now Available

October 24, 2024 12:45 PM

‘Stem Cells: The Secret of Reverse- Aging' by Dr. Jeong Chan Ra, founder of Nature Cell and director of Biostar Stem Cell Research Institute has been expertly translated into English in the United States to ensure that readers worldwide can access it through Amazon. It distills 20 years of the author's groundbreaking research and 15 years of practical application.Initially published in Korea on December 25, 2023, the book swiftly achieved sales...

Read more

MelliCell Awarded SEED Grant with Mass General Brigham to Propel Innovation in Diabetes and Obesity

October 24, 2024 10:00 AM

MelliCell Inc., a biotech company pioneering adipocyte therapies for chronic disease, with the support of Mass General Brigham, one of the nation's leading biomedical research organizations with several Harvard Medical School teaching hospitals, is proud to announce a prestigious award from the National Institutes of Health - National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK) SEED Fund. This grant, part of the Small...

Read more

Qr8 Health Cognition Suite Now Available on Epic Vendor Services Platform

October 24, 2024 9:00 AM

Qr8 Health, a leading provider of digital solutions for dementia and other neurological diseases, today announced that its flagship product, Qr8 Cognition SuiteTM, is now available via Epic Vendor Services-one of the world's most widely adopted electronic medical record (EMR) platforms. This new integration method builds on Qr8 Health's strong track record of successful EMR implementations across the US, Canada, and Europe, further enhancing the...

Read more

Alligator Bioscience AB Reports Financial Results for the First 9 Months of 2024 and for Q3 2024 and Provides a Business Update

October 24, 2024 2:20 AM

Alligator Bioscience (STO:ATORX)Recruitment completed of 450 µg/kg back-fill cohort in the mitazalimab OPTIMIZE-1 study in pancreatic cancerPositive interim Phase 1 data evaluating ALG.APV-527 monotherapy in multiple solid tumor types presented at ESMO Congress 2024Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX)"We have made excellent progress over the last few months with preparations for our lead asset mitazalimab's Phase 3...

Read more

SpeeDx Appoints Jeremy Stackawitz as Chief Executive Officer to Drive Global Expansion of Its Molecular Diagnostics Solutions

October 23, 2024 5:00 PM

SYDNEY, AUSTRALIA / ACCESSWIRE / October 23, 2024 / SpeeDx, a leading innovator in molecular diagnostic solutions, today announced the appointment of Jeremy Stackawitz as Chief Executive Officer. With more than 25 years of leadership experience in the life sciences and diagnostics sectors, Stackawitz will focus on accelerating SpeeDx's commercialization, partnering and regulatory activities across key markets, including the United States.Jeremy...

Read more

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

October 23, 2024 8:30 AM

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that TuHURA recently participated at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC. As part of the event, Dr. James Bianco, President and Chief Executive Officer of TuHURA participated in the Precision and...

Read more

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

October 22, 2024 9:00 AM

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that it will present at the Virtual Investor New to the Street Event on Wednesday, October 30, 2024 at 4:00 PM ET.As part of the event, Dr. Jim Bianco, President and Chief Executive Officer of TuHURA will provide a corporate overview...

Read more

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

October 22, 2024 8:45 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024, in Houston, Texas and virtually.Details of the presentation are as...

Read more

Biovica signs agreement with UK biotech company

October 22, 2024 2:20 AM

UPPSALA, SE / ACCESSWIRE / October 22, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in blood-based cancer monitoring, has signed a Master Service Agreement (MSA) for TKa testing with a UK-based pharma biotech company.Under this agreement, Biovica will deliver TKa testing services using its DiviTum® TKa assay and expertise in interpreting TKa measurement dynamics to support drug development and optimize...

Read more

Prolocor Announces Publication of Confirmatory Results From Multicenter 800 Patient Study in the Journal of the American College of Cardiology (JACC)

October 21, 2024 11:00 AM

Greater than 2-fold predictive value (p=0.001) for heart attack, stroke, and deathSignificant unmet need in balancing the risks and benefits of antithrombotic treatment in patients with acute coronary syndrome (ACS)Supports trend in individualized antiplatelet therapyPHILADELPHIA, PA / ACCESSWIRE / October 21, 2024 / Prolocor, Inc., a healthcare startup developing the innovative diagnostic Prolocor pFCG® test that identifies patients at higher...

Read more

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics

October 17, 2024 4:35 PM

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy today announced the completion of its previously announced merger with Kintara Therapeutics, Inc. (now TuHURA Biosciences, Inc.). The combined company will operate under the name "TuHURA Biosciences, Inc." and will focus on advancing TuHURA's innate...

Read more